Solaris SX
Commercial- Indications
- End-Stage Kidney Disease, Peripheral Artery Disease
Company intelligence / Profile preview
Solaris Endovascular
New Orleans, Louisiana, USA
- Ownership
- Private
- Development stage
- Commercial
01
Overview
The Solaris SX device has demonstrated high patency rates and reduced restenosis compared to controls in preclinical studies. The device is already used clinically outside the United States with over 13,000 units sold globally. The new drug-eluting version aims to further reduce edge stenosis using sirolimus.
- Therapeutic areas
- CardiovascularNephrology
- Modalities
- DeviceDrug-eluting stent graftStent graft
- Industry
- Implantable Medical Devices
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Acquired worldwide rights to core technologies from Scitech Medical.
Beyond the preview
Go deeper on Solaris Endovascular.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solaris Endovascular.